Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton Nov 23, 2023 11:29am
232 Views
Post# 35750094

RE:RE:RE:RE:RE:RE:RE:RE:RE:comgrats

RE:RE:RE:RE:RE:RE:RE:RE:RE:comgratsMugsy - your point I was in disagreed with was outside Otena pipeline. As in their other pipeline (currently preclinicial) that have for over five years gone no where but the company has spent millions on. I'm fine with them focusing on chronic after a successful PH2 and PH3 of acute as well as their preclinicial drugs but to state that those drugs (chronic which has to be restarted and preclinicial) add value without costing tens of millions to advance is not correct / data backs up that preclinical drugs are not valued by the market. Yes I agree that hydrogen sulfide platform could be far reaching/expasive but let's be frank. Dan and team have one shot at goal that can save many under water shareholders and the company's viability. The less capital wasted IMO on the preclinical pipeline / chronic the better. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities